施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMY 施贵宝

盘前交易 03-25 08:09:36 EDT

57.39

+0.39

+0.68%

盘前57.76

+0.37+0.64%

08:07 EDT

最高57.69	最低56.45	成交量1,200万
今开56.80	昨收57.00	日振幅2.18%
总市值1,168亿	流通市值1,166亿	总股本20.36亿
成交额6.87亿	换手率0.59%	流通股本20.32亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMY","market":"US","secType":"STK","nameCN":"施贵宝","latestPrice":57.39,"timestamp":1774382400000,"preClose":57,"halted":0,"volume":11997698,"hourTrading":{"tag":"盘前","latestPrice":57.76,"preClose":57.39,"latestTime":"08:07 EDT","volume":2153,"amount":124710.255738,"timestamp":1774440440735,"change":0.37,"changeRate":0.006447,"amplitude":0.009584},"delay":0,"changeRate":0.0068421052631579046,"floatShares":2031646263,"shares":2035753027,"eps":3.46,"marketStatus":"盘前交易","change":0.39,"latestTime":"03-25 08:09:36 EDT","open":56.8,"high":57.69,"low":56.45,"amount":687419864.65404,"amplitude":0.021754,"askPrice":58.55,"askSize":150,"bidPrice":57.5,"bidSize":602,"shortable":3,"etf":0,"ttmEps":3.46,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774445400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":-18475200000,"exchange":"NYSE","adjPreClose":57.39,"dividendRate":0.0434,"preHourTrading":{"tag":"盘前","latestPrice":57.76,"preClose":57.39,"latestTime":"08:07 EDT","volume":2153,"amount":124710.255738,"timestamp":1774440440735,"change":0.37,"changeRate":0.006447,"amplitude":0.009584},"postHourTrading":{"tag":"盘后","latestPrice":57.49,"preClose":57.39,"latestTime":"19:57 EDT","volume":4618297,"amount":265044339.281599,"timestamp":1774396657394,"change":0.1,"changeRate":0.001742,"amplitude":0.002595},"volumeRatio":0.5188187827926569,"impliedVol":0.3186,"impliedVolPercentile":0.448},"requestUrl":"/m/hq/s/BMY","defaultTab":"news","newsList":[{"id":"1148811954","title":"施贵宝公布Camzyos新数据，巩固其在梗阻性肥厚型心肌病领域领导地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1148811954","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148811954?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:01","pubTimestamp":1774263670,"startTime":"0","endTime":"0","summary":"在2026年美国心脏病学会年度科学会议暨博览会（ACC.26）上，施贵宝公布了其药物Camzyos（Mavacamten）的最新数据。这些新数据进一步强化了该公司在梗阻性肥厚型心肌病治疗领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1323610961.USD","LU1868837136.USD","LU0114720955.EUR","LU1989771016.USD","LU1670710661.SGD","BK4585","IE0009355771.USD","LU0267386448.USD","IE00B2B36J28.USD","LU0985481810.HKD","LU1093756325.SGD","LU1261432733.SGD","LU2242652126.USD","LU0456855351.SGD","LU0868494617.USD","BMY","BK4007","LU1430594728.SGD","LU2125154778.USD","LU2242646821.SGD","IE00BSNM7G36.USD","LU1032466523.USD","LU0306807586.USD","LU0096364046.USD","LU1670711040.USD","BK4581","LU1868837300.USD","LU0225284248.USD","IE00BJT1NW94.SGD","LU2125154935.USD","BK4559","LU0237698245.USD","LU1571399168.USD","IE00BFTCPJ56.SGD","LU1670710588.SGD","LU1868836591.USD","BK4588","LU1585245621.USD","LU1670711123.USD","LU1868836757.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU0225771236.USD","LU2360032135.SGD","LU1883839398.USD","LU0321505868.SGD","LU0061475181.USD","LU0321505439.SGD","LU0306806265.USD","LU0882574055.USD","LU1074936037.SGD","BK4534","LU1093756168.USD","IE00BFXG1179.USD","LU2133065610.SGD","LU1868836914.USD","LU1718418525.SGD","LU1291159041.SGD"],"gpt_icon":0},{"id":"1197973313","title":"FDA授予纳武利尤单抗传统批准 用于自体造血干细胞移植及维布妥昔单抗治疗后复发或难治性经典霍奇金淋巴瘤成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1197973313","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197973313?lang=zh_cn&edition=full","pubTime":"2026-03-21 00:16","pubTimestamp":1774023393,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式授予纳武利尤单抗（Nivolumab）传统批准，该药物适用于曾接受自体造血干细胞移植（HSCT）及维布妥昔单抗（Brentuximab Vedotin）治疗后，病情出现复发或难治性的经典霍奇金淋巴瘤（cHL）成年患者。\n此次传统批准的授予，标志着该免疫疗法在治疗这一特定患者群体方面获得了监管机构的全面认可。纳武利尤单抗由施贵宝（Bristol-Myers Squibb）研发，是一种PD-1抑制剂，能够通过激活人体自身的免疫系统来攻击癌细胞。\n这一决定为患有复发或难治性经典霍奇金淋巴瘤的成人提供了新的重要治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1323610961.USD","LU1291159041.SGD","LU0114720955.EUR","IE0009355771.USD","IE00BSNM7G36.USD","LU1670710588.SGD","LU1989771016.USD","LU1571399168.USD","LU1868837136.USD","IE0002141913.USD","BK4007","LU2242652126.USD","LU0237698245.USD","LU2360032135.SGD","BK4585","LU0061475181.USD","IE00BFXG1179.USD","LU1093756325.SGD","LU0096364046.USD","LU0225771236.USD","LU1670711123.USD","LU1868837300.USD","BK4532","LU0306806265.USD","BK4588","LU1585245621.USD","LU1032466523.USD","LU0321505868.SGD","LU1074936037.SGD","LU1430594728.SGD","LU1261432733.SGD","BK4581","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU0456855351.SGD","LU0321505439.SGD","BK4534","LU2133065610.SGD","LU2125154778.USD","LU0868494617.USD","LU1718418525.SGD","LU1868836591.USD","LU2125154935.USD","LU1883839398.USD","BK4559","LU1093756168.USD","IE00BFTCPJ56.SGD","LU0306807586.USD","LU1868836757.USD","LU1868836914.USD","LU0225284248.USD","LU1670711040.USD","IE00BJT1NW94.SGD","LU0267386448.USD","LU0985481810.HKD","IE00B2B36J28.USD","LU0882574055.USD","BMY","LU1670710661.SGD"],"gpt_icon":0},{"id":"2620238733","title":"杰富瑞上调施贵宝目标价至70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620238733","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620238733?lang=zh_cn&edition=full","pubTime":"2026-03-18 15:48","pubTimestamp":1773820082,"startTime":"0","endTime":"0","summary":"杰富瑞将施贵宝的目标价从68美元上调至70美元，维持“买入”评级。(格隆汇)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260318/32078061.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BMY"],"gpt_icon":0},{"id":"2619115423","title":"FDA批准百时美施贵宝(BMY.US)TYK2抑制剂氘可来昔替尼治疗活动性银屑病关节炎成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2619115423","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619115423?lang=zh_cn&edition=full","pubTime":"2026-03-13 07:00","pubTimestamp":1773356416,"startTime":"0","endTime":"0","summary":"百时美施贵宝(BMY.US)宣布，美国食品药品监督管理局(FDA)已批准颂狄多®(氘可来昔替尼)用于治疗活动性银屑病关节炎(PsA)成人患者。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20260313/20260313065958_28723.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260313/20260313065958_28723.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0306806265.USD","LU1323610961.USD","LU1585245621.USD","LU2242652126.USD","BMY","LU1868836914.USD","LU0868494617.USD","BK4559","LU0225771236.USD","LU1670710588.SGD","IE00BFTCPJ56.SGD","BK4534","LU0225284248.USD","LU1093756168.USD","LU2125154778.USD","LU0306807586.USD","IE00BJT1NW94.SGD","BK4581","IE0002141913.USD","LU0061475181.USD","IE00B2B36J28.USD","LU1989771016.USD","IE00BSNM7G36.USD","LU1430594728.SGD","LU1868836591.USD","LU1868837300.USD","LABU","LU1868836757.USD","LU0456855351.SGD","LU1718418525.SGD","LU1093756325.SGD","IE00BFXG1179.USD","IE0009355771.USD","LU0321505439.SGD","LU1670711123.USD","LU1670710661.SGD","LU1883839398.USD","LU0882574055.USD","LU0985481810.HKD","LU1032466523.USD","LU1261432733.SGD","BK4532","LU0237698245.USD","BK4588","LU0267386448.USD","LU2360032135.SGD","LU2125154935.USD","LU1868837136.USD","BK4007","LU0114720955.EUR"],"gpt_icon":0},{"id":"1103858181","title":"施贵宝公布口服Mezigdomide治疗复发或难治性多发性骨髓瘤的Successor-2研究积极3期结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1103858181","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103858181?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:00","pubTimestamp":1773054013,"startTime":"0","endTime":"0","summary":"施贵宝宣布，其口服药物Mezigdomide针对复发或难治性多发性骨髓瘤的Successor-2研究取得积极3期临床试验结果。该研究达到了主要终点，显示患者无进展生存期显著改善。\n安全性方面，Mezigdomide表现出可控的安全性特征，与既往研究一致。详细数据将在即将召开的医学会议上公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125154778.USD","LU1868836757.USD","LU1571399168.USD","LU1032466523.USD","BK4588","LU1670711040.USD","IE00B2B36J28.USD","LU0985481810.HKD","LU1868836591.USD","LU1093756325.SGD","LU0456855351.SGD","LU2242652126.USD","IE00BJT1NW94.SGD","BK4581","LU0096364046.USD","LU0267386448.USD","LU0225284248.USD","LU1670710661.SGD","LU1585245621.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU1868837300.USD","LU0061475181.USD","LU0114720955.EUR","LU1989771016.USD","IE0002141913.USD","LU1093756168.USD","BK4007","LU1670710588.SGD","LU2242646821.SGD","LU0868494617.USD","IE00BSNM7G36.USD","LU0321505868.SGD","LU0882574055.USD","LU1261432733.SGD","LU1868836914.USD","LU1670711123.USD","LU0306807586.USD","LU1883839398.USD","LU2133065610.SGD","LU2360032135.SGD","BK4532","LU0225771236.USD","LU1718418525.SGD","LU1323610961.USD","LU2125154935.USD","LU0237698245.USD","LU1868837136.USD","BMY","LU1074936037.SGD","BK4585","IE00BFXG1179.USD","LU0306806265.USD","IE00BFTCPJ56.SGD","LU0321505439.SGD","LU1291159041.SGD","BK4534","BK4559","LU1430594728.SGD"],"gpt_icon":0},{"id":"1136008921","title":"施贵宝旗下Mezikd在RRMM治疗中展现无进展生存期显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1136008921","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136008921?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:00","pubTimestamp":1773054012,"startTime":"0","endTime":"0","summary":"施贵宝公司近日公布，其研发的药物Mezikd在针对复发或难治性多发性骨髓瘤（RRMM）的临床试验中，取得了无进展生存期（PFS）的显著改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2125154935.USD","BK4588","LU0225284248.USD","LU1430594728.SGD","BMY","LU0096364046.USD","LU0985481810.HKD","BK4585","LU0061475181.USD","LU1868836591.USD","BK4559","LU1093756325.SGD","LU0456855351.SGD","LU1291159041.SGD","LU1868837300.USD","BK4534","BK4532","LU0321505868.SGD","LU1718418525.SGD","LU0306806265.USD","LU0321505439.SGD","LU1571399168.USD","IE00B2B36J28.USD","LU1093756168.USD","LU1868837136.USD","BK4007","LU0882574055.USD","LU1032466523.USD","LU1323610961.USD","LU1585245621.USD","LU0237698245.USD","LU2360032135.SGD","LU1989771016.USD","IE00BSNM7G36.USD","LU0267386448.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0306807586.USD","LU2242652126.USD","LU0868494617.USD","LU1074936037.SGD","LU1670711123.USD","LU1868836914.USD","BK4581","LU1868836757.USD","LU2133065610.SGD","LU0114720955.EUR","IE00BFXG1179.USD","IE0002141913.USD","LU2125154778.USD","LU2242646821.SGD","IE0009355771.USD","LU1670710588.SGD","LU1670711040.USD","LU1670710661.SGD","LU1261432733.SGD","LU1883839398.USD","LU0225771236.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"1156464014","title":"美国FDA批准施贵宝Sotyktu®（Deucravacitinib）用于治疗活动性银屑病关节炎成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1156464014","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156464014?lang=zh_cn&edition=full","pubTime":"2026-03-07 10:59","pubTimestamp":1772852352,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式批准施贵宝公司研发的Sotyktu®（通用名：Deucravacitinib）用于治疗成人活动性银屑病关节炎。这一决定为患者提供了一种全新的口服治疗选择，有望显著改善其生活质量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1670711123.USD","LU1868837300.USD","LU1868836914.USD","LU0114720955.EUR","LU0267386448.USD","IE0002141913.USD","BK4588","IE00B2B36J28.USD","LU1989771016.USD","LU1868836591.USD","LU1718418525.SGD","LU0306806265.USD","LU0321505868.SGD","IE0009355771.USD","LU0225771236.USD","BK4532","LU1291159041.SGD","LU0882574055.USD","LU1261432733.SGD","LU0868494617.USD","LU2125154778.USD","LU0061475181.USD","LU2242646821.SGD","LU0096364046.USD","LU0985481810.HKD","LU0306807586.USD","LU1093756325.SGD","LU1074936037.SGD","IE00BSNM7G36.USD","IE00BJT1NW94.SGD","LU0225284248.USD","LU1585245621.USD","BMY","LU1883839398.USD","LU0237698245.USD","LU0456855351.SGD","LU1323610961.USD","BK4559","LU1032466523.USD","LU1868837136.USD","LU2360032135.SGD","BK4007","BK4581","LU1670710661.SGD","LU1430594728.SGD","IE00BFTCPJ56.SGD","LU1093756168.USD","LU0321505439.SGD","BK4534","LU1571399168.USD","LU2133065610.SGD","LU1670710588.SGD","LU1868836757.USD","LU2242652126.USD","IE00BJJMRZ35.SGD","LU2125154935.USD","LU1670711040.USD","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2617304590","title":"上海医药这次割肉有点狠","url":"https://stock-news.laohu8.com/highlight/detail?id=2617304590","media":"指针Point","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617304590?lang=zh_cn&edition=full","pubTime":"2026-03-05 08:31","pubTimestamp":1772670705,"startTime":"0","endTime":"0","summary":"作者|黄宇晨编辑| 方  乔近期，上海医药对外发布公告称，其将以不低于10.23亿元人民币的底价，借助公开挂牌的途径，转让持有的中美上海施贵宝制药有限公司30%的股权。对上海医药来说，出售中美施贵宝股权，是主动调整资产，也反映出其正面临结构性压力。在此情况下，上海医药主动叫停效益差的项目。与此同时，上海医药正加速推进创新药布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305085909a44d3268&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305085909a44d3268&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2125154935.USD","BK4588","LU0225284248.USD","LU1430594728.SGD","BMY","LU0096364046.USD","LU0985481810.HKD","BK4585","LU0061475181.USD","LU1868836591.USD","BK4559","LU1093756325.SGD","LU0456855351.SGD","LU1291159041.SGD","LU1868837300.USD","BK4534","BK4532","LU0321505868.SGD","LU1718418525.SGD","LU0321505439.SGD","LU1571399168.USD","LU1868837136.USD","BK4007","LU0882574055.USD","LU1032466523.USD","LU0237698245.USD","IE00BSNM7G36.USD","LU0267386448.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0306807586.USD","LU2242652126.USD","LU0868494617.USD","LU1074936037.SGD","LU1670711123.USD","LU1868836914.USD","BK4581","LU1868836757.USD","LU2133065610.SGD","LU0114720955.EUR","IE0002141913.USD","LU2125154778.USD","LU2242646821.SGD","BMS","LU1670710588.SGD","LU1670711040.USD","LU1261432733.SGD","02607","LU1883839398.USD","LU0225771236.USD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2613799350","title":"Piper Sandler上调施贵宝目标价至75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613799350","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613799350?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:07","pubTimestamp":1771924028,"startTime":"0","endTime":"0","summary":"Piper Sandler将施贵宝的目标价从66美元上调至75美元，维持“增持”评级。(格隆汇)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260224/32023666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BMY"],"gpt_icon":0},{"id":"1103835253","title":"施贵宝公布Luspatercept治疗成人α-地中海贫血注册性II期研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1103835253","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103835253?lang=zh_cn&edition=full","pubTime":"2026-02-23 19:59","pubTimestamp":1771847954,"startTime":"0","endTime":"0","summary":"施贵宝宣布，其针对成人α-地中海贫血患者开展的Luspatercept注册性II期临床试验获得积极顶线结果。该研究达到了主要终点，显示Luspatercept在提升血红蛋白水平方面具有显著疗效。安全性数据与既往研究一致，未发现新的安全隐患。\n这一突破性进展为α-地中海贫血患者带来了新的治疗希望。Luspatercept作为首个在该适应症中显示潜力的创新疗法，有望填补当前治疗领域的空白。公司计划与监管机构讨论后续注册路径，加速推动该药物惠及全球患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU1571399168.USD","IE0002141913.USD","BK4585","LU2125154778.USD","LU0868494617.USD","LU0267386448.USD","LU1868836757.USD","LU1989771016.USD","BK4581","LU0061475181.USD","LU1323610961.USD","LU0225771236.USD","LU1032466523.USD","BK4007","IE00BSNM7G36.USD","LU1585245621.USD","LU1718418525.SGD","LU2360032135.SGD","LU0321505868.SGD","LU1093756168.USD","IE00BFTCPJ56.SGD","LU0456855351.SGD","IE00BFXG1179.USD","LU1261432733.SGD","LU1670711123.USD","LU1291159041.SGD","LU1883839398.USD","LU2133065610.SGD","LU0306806265.USD","IE0009355771.USD","LU1074936037.SGD","BK4534","BK4588","LU0114720955.EUR","LU1868836591.USD","LU1868837136.USD","IE00B2B36J28.USD","LU1093756325.SGD","LU0306807586.USD","LU0096364046.USD","LU2242646821.SGD","LU1868836914.USD","LU0985481810.HKD","LU1670711040.USD","LU0882574055.USD","LU2125154935.USD","LU1670710661.SGD","LU1430594728.SGD","LU0321505439.SGD","BMY","LU2242652126.USD","LU1868837300.USD","LU0225284248.USD","LU1670710588.SGD","LU0237698245.USD","IE00BJT1NW94.SGD","BK4559","BK4532"],"gpt_icon":0},{"id":"2612392451","title":"美国FDA受理百时美施贵宝伊伯度胺(Iberdomide)的新药上市申请。","url":"https://stock-news.laohu8.com/highlight/detail?id=2612392451","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612392451?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:00","pubTimestamp":1771329628,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1670711123.USD","LU1868836591.USD","LU0114720955.EUR","LU1670711040.USD","LU1989771016.USD","LU2360032135.SGD","LU0267386448.USD","LU0096364046.USD","LU1032466523.USD","BK4585","IE0002141913.USD","LU0225284248.USD","LU1093756325.SGD","LU1868836914.USD","LU1074936037.SGD","IE00BSNM7G36.USD","LU0306806265.USD","LU0306807586.USD","LU1883839398.USD","LU2242646821.SGD","IE00BFXG1179.USD","LU1670710661.SGD","LU2125154778.USD","LU0321505868.SGD","BK4588","LU1291159041.SGD","LU1585245621.USD","BK4559","LU0882574055.USD","LU1868837136.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0225771236.USD","LU1261432733.SGD","IE00BJT1NW94.SGD","LU1571399168.USD","LU0456855351.SGD","LU1670710588.SGD","LU1718418525.SGD","BK4581","BMY","LU0868494617.USD","LU2125154935.USD","LU2242652126.USD","LU0061475181.USD","BK4534","LU0985481810.HKD","LU2133065610.SGD","BK4532","LU1430594728.SGD"],"gpt_icon":0},{"id":"1143149074","title":"美国FDA受理施贵宝针对复发或难治性多发性骨髓瘤患者的新药Iberdomide上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1143149074","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143149074?lang=zh_cn&edition=full","pubTime":"2026-02-17 20:00","pubTimestamp":1771329615,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式受理施贵宝（Bristol-Myers Squibb）提交的新药Iberdomide上市申请，该药物旨在治疗复发或难治性多发性骨髓瘤患者。这一进展标志着施贵宝在血液肿瘤领域研发的重要里程碑，为患者提供了新的治疗希望。\n多发性骨髓瘤作为一种恶性血液疾病，复发或难治性病例的治疗选择有限，临床需求迫切。Iberdomide作为一种创新疗法，其申请获受理意味着FDA将基于现有数据展开审评，未来可能加速该药物的上市进程。施贵宝持续投入研发，展现了其在肿瘤治疗领域的战略布局与执行力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0237698245.USD","IE0002141913.USD","LU1670711040.USD","IE00BSNM7G36.USD","BK4588","LU0456855351.SGD","LU2242646821.SGD","LU1883839398.USD","LU1585245621.USD","LU1868836757.USD","BK4007","LU1670710588.SGD","LU0306806265.USD","IE00BJT1NW94.SGD","LU1323610961.USD","LU0225771236.USD","LU0306807586.USD","LU1074936037.SGD","IE00BFTCPJ56.SGD","LU1261432733.SGD","LU1571399168.USD","BK4532","LU1093756168.USD","LU1718418525.SGD","LU1868837136.USD","LU2125154935.USD","LU0267386448.USD","LU2125154778.USD","LU1670710661.SGD","LU1291159041.SGD","LU1032466523.USD","BK4585","IE0009355771.USD","LU0868494617.USD","LU2133065610.SGD","IE00BFXG1179.USD","LU2242652126.USD","LU1093756325.SGD","LU2360032135.SGD","LU0096364046.USD","LU0985481810.HKD","LU1670711123.USD","LU1868836591.USD","LU0321505439.SGD","BMY","LU1989771016.USD","LU0061475181.USD","LU0114720955.EUR","BK4534","LU1868836914.USD","LU1868837300.USD","LU1430594728.SGD","BK4559","LU0321505868.SGD","IE00B2B36J28.USD","LU0225284248.USD","IE00BJJMRZ35.SGD","BK4581","LU0882574055.USD"],"gpt_icon":0},{"id":"2610261682","title":"古根海姆上调施贵宝目标价至72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610261682","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610261682?lang=zh_cn&edition=full","pubTime":"2026-02-09 15:47","pubTimestamp":1770623221,"startTime":"0","endTime":"0","summary":"古根海姆将施贵宝的目标价从62美元上调至72美元，维持“买入”评级。(格隆汇)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260209/32007330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BMY"],"gpt_icon":0},{"id":"1128483540","title":"异动解读 | 施贵宝盘中大涨5.06%，业绩超预期及乐观展望提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1128483540","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128483540?lang=zh_cn&edition=full","pubTime":"2026-02-05 22:56","pubTimestamp":1770303394,"startTime":"0","endTime":"0","summary":"施贵宝（BMY）今日盘中大涨5.06%，引起了市场的广泛关注。消息面上，公司发布的第四季度业绩超出市场预期，同时给出了高于分析师预测的2026年营收和利润指引，显示出强劲的增长前景。具体而言，其癌症免疫疗法Opdivo销售强劲，血液稀释剂Eliquis的降价策略有望推动收入增长并避免潜在罚款，加之成本削减计划取得进展，共同增强了投资者信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BMY"],"gpt_icon":0},{"id":"1125300301","title":"施贵宝高管预计：2027年Eliquis销售额将较2026年下滑15亿至20亿美元——电话会议披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1125300301","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125300301?lang=zh_cn&edition=full","pubTime":"2026-02-05 21:21","pubTimestamp":1770297716,"startTime":"0","endTime":"0","summary":"在最新电话会议中，施贵宝高管透露，公司预计2027年抗凝血药物Eliquis的销售额将较2026年出现显著回落，下降幅度预计在15亿至20亿美元区间。这一预测反映出该明星药物在专利到期后可能面临的市场挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225771236.USD","LU1430594728.SGD","IE00B2B36J28.USD","LU0267386448.USD","IE00BFXG1179.USD","LU1718418525.SGD","LU1571399168.USD","LU1670711040.USD","BMY","LU1032466523.USD","LU1323610961.USD","IE00BSNM7G36.USD","LU0321505868.SGD","LU1883839398.USD","LU1261432733.SGD","IE0009355771.USD","LU2242652126.USD","BK4007","LU1093756168.USD","BK4532","LU1093756325.SGD","LU1670710588.SGD","LU1670710661.SGD","LU1868836757.USD","LU0306807586.USD","IE00BJJMRZ35.SGD","LU0096364046.USD","LU0456855351.SGD","LU0868494617.USD","IE00BJT1NW94.SGD","LU0321505439.SGD","LU1868836914.USD","LU1868836591.USD","LU2360032135.SGD","LU0225284248.USD","BK4534","LU1989771016.USD","LU0114720955.EUR","BK4559","LU1291159041.SGD","LU0985481810.HKD","LU2125154935.USD","LU0061475181.USD","LU0237698245.USD","LU0882574055.USD","LU1585245621.USD","LU1868837136.USD","BK4588","LU1074936037.SGD","LU2133065610.SGD","LU2242646821.SGD","BK4581","BK4585","LU1670711123.USD","LU2125154778.USD","LU0306806265.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU1868837300.USD"],"gpt_icon":0},{"id":"2609374724","title":"百时美施贵宝预计2026年营收约460亿至475亿美元 超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2609374724","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609374724?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:02","pubTimestamp":1770292944,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0868494617.USD","BK4588","LU1032466523.USD","LU0306807586.USD","IE00BFXG1179.USD","LU2125154778.USD","LU1571399168.USD","IE0009355771.USD","LU2125154935.USD","LU0061475181.USD","BK4534","LU0096364046.USD","LU1261432733.SGD","LU0267386448.USD","LU1093756168.USD","LU1430594728.SGD","LU1670711123.USD","IE00BJJMRZ35.SGD","LU0225771236.USD","LU0456855351.SGD","LU0225284248.USD","BMY","LU0114720955.EUR","LU2133065610.SGD","LU1868837300.USD","LU0985481810.HKD","IE00BFTCPJ56.SGD","LU1323610961.USD","BK4007","LU1585245621.USD","LU1670710661.SGD","LU1718418525.SGD","LU2242646821.SGD","LU1989771016.USD","LU1670711040.USD","LU1868836757.USD","BK4559","LU1868836914.USD","BK4581","LU1291159041.SGD","BK4532","LU1670710588.SGD","IE0002141913.USD","LU0321505439.SGD","LU0321505868.SGD","LU1093756325.SGD","LU1883839398.USD","LU0237698245.USD","LU2360032135.SGD","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"1166668975","title":"施贵宝第四季度调整后每股收益受收购IPRD费用及授权收入影响，净额为-0.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166668975","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166668975?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:00","pubTimestamp":1770292803,"startTime":"0","endTime":"0","summary":"施贵宝公司第四季度调整后的每股收益中，计入了因收购相关IPRD（已获产品权益）费用及授权收入所产生的净影响，合计金额为-0.60美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1074936037.SGD","IE0009355771.USD","LU0882574055.USD","LU1868836914.USD","LU0225284248.USD","LU1670710588.SGD","BK4585","BK4532","IE00BFXG1179.USD","LU0114720955.EUR","IE00BJJMRZ35.SGD","LU0061475181.USD","BK4581","BK4588","BMY","LU1585245621.USD","LU0096364046.USD","LU0306806265.USD","IE00BSNM7G36.USD","LU1868836757.USD","LU0985481810.HKD","LU1989771016.USD","LU2242646821.SGD","IE00BFTCPJ56.SGD","LU0321505439.SGD","LU1261432733.SGD","LU1032466523.USD","LU0225771236.USD","IE0002141913.USD","LU0456855351.SGD","LU0868494617.USD","IE00B2B36J28.USD","LU0267386448.USD","LU1670710661.SGD","LU1323610961.USD","LU1868837136.USD","IE00BJT1NW94.SGD","LU1093756168.USD","LU1291159041.SGD","LU1670711040.USD","LU1718418525.SGD","LU2125154778.USD","LU1883839398.USD","BK4007","LU0237698245.USD","BK4559","LU0306807586.USD","LU1571399168.USD","LU1670711123.USD","LU0321505868.SGD","BK4534","LU1093756325.SGD","LU1868836591.USD","LU1430594728.SGD","LU1868837300.USD","LU2242652126.USD","LU2125154935.USD","LU2133065610.SGD","LU2360032135.SGD"],"gpt_icon":0},{"id":"1126049058","title":"Opdivo®与Yervoy®组合疗法获安大略省快速通道项目纳入报销，成为晚期肝癌一线治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1126049058","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126049058?lang=zh_cn&edition=full","pubTime":"2026-02-03 20:03","pubTimestamp":1770120231,"startTime":"0","endTime":"0","summary":"施贵宝公司研发的免疫疗法组合Opdivo®与Yervoy®近日被加拿大安大略省快速通道医疗项目正式纳入报销范围，作为晚期肝细胞癌患者的一线治疗方案。这一决策使更多患者能够及时获得创新疗法的救治机会。\n该组合疗法通过双重免疫机制激活患者自身免疫系统对抗肿瘤，其临床数据显著优于传统治疗方案。安大略省卫生部门指出，将创新药物纳入快速报销通道体现了医疗体系对晚期癌症患者迫切需求的积极响应。\n此次纳入报销范围的决定预计将惠及省内数百名晚期肝癌患者。医疗专家强调，早期采用有效治疗方案对提升患者生存率和生活质量具有关键意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0985481810.HKD","LU2133065610.SGD","LU0237698245.USD","BK4532","LU0096364046.USD","LU2125154935.USD","LU1670711040.USD","IE00BJJMRZ35.SGD","LU1430594728.SGD","IE0009355771.USD","LU1074936037.SGD","LU1989771016.USD","BK4559","IE0002141913.USD","IE00B2B36J28.USD","LU1868836591.USD","BK4581","IE00BFTCPJ56.SGD","LU0267386448.USD","LU1670710588.SGD","BK4585","LU0456855351.SGD","LU1868837136.USD","LU2242652126.USD","LU0061475181.USD","LU1718418525.SGD","LU1093756325.SGD","LU1261432733.SGD","LU0225284248.USD","BMY","IE00BFXG1179.USD","LU1670710661.SGD","LU1093756168.USD","BK4588","LU1868837300.USD","LU2125154778.USD","BK4534","LU1868836914.USD","IE00BJT1NW94.SGD","LU0306806265.USD","LU0321505868.SGD","LU2242646821.SGD","LU0321505439.SGD","LU1291159041.SGD","LU1585245621.USD","LU1868836757.USD","LU0882574055.USD","LU1032466523.USD","LU0225771236.USD","LU1670711123.USD","LU2360032135.SGD","LU0114720955.EUR","LU1883839398.USD","IE00BSNM7G36.USD","LU1571399168.USD","LU1323610961.USD","LU0868494617.USD","LU0306807586.USD"],"gpt_icon":0},{"id":"2605149493","title":"生物制药公司Janux Therapeutics与施贵宝达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2605149493","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605149493?lang=zh_cn&edition=full","pubTime":"2026-01-22 21:47","pubTimestamp":1769089661,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BJJMRZ35.SGD","LU1291159041.SGD","LU1093756168.USD","LU1868836591.USD","LENZ","LU1074936037.SGD","BMY","IE00BJT1NW94.SGD","LU2242646821.SGD","LU1868837300.USD","LU0061475181.USD","LU1430594728.SGD","LU1868836914.USD","BK4534","BK4588","LU1718418525.SGD","LU0114720955.EUR","BK4139","LU0096364046.USD","LU0306806265.USD","IE0009355771.USD","IE00BSNM7G36.USD","BK4007","IE00BFXG1179.USD","LU0225284248.USD","LU0868494617.USD","LU1868837136.USD","LU1989771016.USD","BK4539","LU0306807586.USD","BK4585","LU0985481810.HKD","LU1323610961.USD","LU0225771236.USD","LU2125154935.USD","LU1585245621.USD","LU0237698245.USD","LU1261432733.SGD","BK4559","JANX","LU1571399168.USD","LU1093756325.SGD","LU1670710661.SGD","LU1670710588.SGD","LU0321505439.SGD","LU1670711123.USD","LU2242652126.USD","LU0456855351.SGD","IE00B2B36J28.USD","IE0002141913.USD"],"gpt_icon":0},{"id":"2605435278","title":"百时美施贵宝 (BMS) CAR-T疗法启动III期临床，治疗自免疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=2605435278","media":"细胞治疗前沿","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605435278?lang=zh_cn&edition=full","pubTime":"2026-01-21 09:53","pubTimestamp":1768960424,"startTime":"0","endTime":"0","summary":"近日，美国临床试验收录网显示，百时美施贵宝的 CD19 CAR-T 细胞疗法 Zola-cel启动了首个 Ⅲ 期临床试验，治疗活动性系统性硬化症。Zola-cel是BMS基于NEX-T平台开发的一款CD19 CAR-T细胞疗法，于2020年进入临床阶段。2019年，BMS以740亿美元完成对Celgene的收购，借此将两款关键CAR-T疗法Breyanzi与Abecma纳入其产品管线，正式踏入细胞治疗领域。BMS积极布局，不断强化其在下一代细胞治疗领域的战略纵深。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012110365897a2adbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012110365897a2adbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4581","LU0114720955.EUR","LU1032466523.USD","IE00BFXG1179.USD","LU1291159041.SGD","IE0002141913.USD","LU2125154778.USD","LU2242652126.USD","LU1261432733.SGD","CAR","LU0306807586.USD","LU0267386448.USD","LU2125154935.USD","LU0096364046.USD","LU1323610961.USD","LU0321505439.SGD","LU1670710661.SGD","LU0321505868.SGD","BK4134","BK4534","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","LU0882574055.USD","LU1670711040.USD","IE00BJJMRZ35.SGD","III","LU1868836914.USD","LU1868836591.USD","LU1868836757.USD","BK4585","BMS","LU2360032135.SGD","LU0306806265.USD","BK4559","LU1989771016.USD","LU0225284248.USD","LU1571399168.USD","LU0985481810.HKD","LU0225771236.USD","LU0061475181.USD","LU1718418525.SGD","LU1670711123.USD","LU2133065610.SGD","BK4007","BMY","BK4588","IE00BJT1NW94.SGD","LU1868837136.USD","LU0868494617.USD","BK4532"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bms.com","stockEarnings":[{"period":"1week","weight":-0.0389},{"period":"1month","weight":-0.0539},{"period":"3month","weight":0.049},{"period":"6month","weight":0.322},{"period":"1year","weight":-0.06},{"period":"ytd","weight":0.064}],"compareEarnings":[{"period":"1week","weight":-0.0263},{"period":"1month","weight":-0.0526},{"period":"3month","weight":-0.0539},{"period":"6month","weight":-0.0074},{"period":"1year","weight":0.1378},{"period":"ytd","weight":-0.0421}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"百时美施贵宝公司于1933年8月在美国德拉瓦州注册成立，源自于1887年在纽约创办的企业，并在1989年因合并而重命名。作为一家生物制药公司，百时美施贵宝专注于创新药物的发现、开发、许可、生产、营销和销售，以对抗严重疾病。公司的战略方法结合了大型制药公司的资源和规模，以及生物技术行业特有的灵活性和创新重点。百时美施贵宝优先关注肿瘤学、血液学、免疫学、心血管和神经科学等领域的变革性药物，旨在提供长期价值和竞争优势。作为全球研究型制药公司，百时美施贵宝的产品在全球范围内销售，服务于包括批发商、分销商和特药药房在内的多种实体，并在多个国家保持着重要的生产运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.478261,"avgChangeRate":-0.011323},{"month":2,"riseRate":0.565217,"avgChangeRate":0.011855},{"month":3,"riseRate":0.630435,"avgChangeRate":0.006826},{"month":4,"riseRate":0.478261,"avgChangeRate":-0.005913},{"month":5,"riseRate":0.565217,"avgChangeRate":0.002647},{"month":6,"riseRate":0.608696,"avgChangeRate":0.009417},{"month":7,"riseRate":0.413043,"avgChangeRate":-0.001733},{"month":8,"riseRate":0.521739,"avgChangeRate":-0.001022},{"month":9,"riseRate":0.521739,"avgChangeRate":0.00993},{"month":10,"riseRate":0.586957,"avgChangeRate":0.025121},{"month":11,"riseRate":0.630435,"avgChangeRate":0.022318},{"month":12,"riseRate":0.630435,"avgChangeRate":0.022265}],"exchange":"NYSE","name":"施贵宝","nameEN":"Bristol-Myers Squibb"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"施贵宝,BMY,施贵宝股票,施贵宝股票老虎,施贵宝股票老虎国际,施贵宝行情,施贵宝股票行情,施贵宝股价,施贵宝股市,施贵宝股票价格,施贵宝股票交易,施贵宝股票购买,施贵宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}